Product launches are slow and are not supported by marketing or R&D. (because they really don't exist anymore in a practical way)
Organizational changes are minimal and predictably chaotic.
Only planned facility closing but no announcements of actual facility closings.
Layoffs are complete and no major layoffs will occur in the near future.
New acquisitions are small and and the planned big acquisition may never happen
Pharma Cafe posts just talk about past layoffs and the "new now old boring to talk about" business model
In essence Valeant the once fast growing acquisition company is becoming a slow growth maker of generic pharmaceuticals, and some consumer products.
Wall Street will lose interest in this company within a year unless the merger of equals happens.
Organizational changes are minimal and predictably chaotic.
Only planned facility closing but no announcements of actual facility closings.
Layoffs are complete and no major layoffs will occur in the near future.
New acquisitions are small and and the planned big acquisition may never happen
Pharma Cafe posts just talk about past layoffs and the "new now old boring to talk about" business model
In essence Valeant the once fast growing acquisition company is becoming a slow growth maker of generic pharmaceuticals, and some consumer products.
Wall Street will lose interest in this company within a year unless the merger of equals happens.